Satellos Bioscience Inc ICOTF

Primary Symbol: T.MSCL Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

TSX:MSCL - Post by User

Satellos Bioscience Inc > Third Quarter Financials

<< Previous

Bullboard Posts

Next >>

Comment by Progress6666on Dec 01, 2018 10:27am

83 Views

Post# 29049219

RE:RE:RE:RE:RE:RE:RE:RE:RE:Third Quarter Financials

Oufff la question a 1 million lol moi dans un scenario optimiste moyen je m imagine avoir un communiquez avant Noel je me donne jusqu a fin janvier... gros max 15 fevrier 2019.... pour y voir un peu plus claire oubligatoirement il va y avoir un financement...... avec ou sans impact a la hausse ......ou l apparition d'un partenaire ou meme si la chance es la un rachat a plusieurs million

<< Previous

Bullboard Posts

Next >>

Morning Market Outlook for Nov. 15, 2024